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Health andWellness Survey (NHWS) in Brazil.. QOL was measured by the physical
component score (PCS) and mental component score (MCS) of the Short Form-12
(SF-12). Loss of work/productivity was measured by the validated Work Productiv-
ity and Activity Impairment instrument. Medical resource utilization was mea-
sured by health care provider, emergency room visits and hospitalization in the
past 6 months. RESULTS: Of the 12,000 respondents, 215 (1.6%) were identified as
AD patient’s caregivers where 63.7% were women. The age group with the highest
proportion of caregivers was 45-54yrs old (36.2%), and they are significantly older
than non-caregivers (44.7 vs. 40.8, p0.05). AD caregivers group reported more
specific co-morbidities (insomnia 33.8%, cardiac arrhythmia 20.7%), similar mean
scores of PCS (49.8 vs. 49.7) andMCS (47.3 vs. 46.9), similar percentage of emergency
roomvisits (21.5% vs. 21.8%), and similar percentage of hospitalization visits (9.9 vs.
9.8) over the past 6months compared to the group of not caregivers of AD patients.
Furthermore, caregivers of AD patients’ group reported 22.3% impairment in daily
activity compared to 22.1% in the group of not caregivers of AD patients.
CONCLUSIONS: From the Brazil NHWS results, AD caregivers suffer from impair-
ment in QOL, work/productivity loss and more specific co-morbidities. Findings
indicate there is still an unmet medical need in AD caregivers in Brazil.
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OBJECTIVES: The majority of currently approved disease-modifying therapies for
Multiple Sclerosis (MS) are injectables; however, there is no validated injection
satisfaction questionnaire for patients with MS. The Satisfaction with Injection
Experience (SIE) questionnaire was developed as a reliable and valid scale to eval-
uate this critical aspect of MS treatment satisfaction. METHODS: The medical lit-
erature was reviewed to determine the domains that were relevant to MS injection
satisfaction. Five domains were identified, along with the most commonly used
response options and recall period. A draft SIE questionnaire was evaluated in
cognitive debriefing interviews with MS patients. The final 5-item SIE question-
naire utilized a 2-week recall period, a 5-point Likert scale, and was scored as an
unweighted mean composite with higher scores representing greater satisfaction.
Preliminary psychometric analyses were conducted using baseline data from EN-
CORE, a multicenter clinical trial designed to investigate 2 formulations of glati-
ramer acetate (GA) for subcutaneous injection. Data were analyzed using item-
total Spearman correlations, Cronbach’s alpha, and principal components
analysis.RESULTS:Complete datawere available for 142MSpatientswhohad been
on the currentlymarketed 20mg formulation of GA utilizing the autoject 2 for glass
syringe for at least 90 days (mean 4.8 years; SD 3.6). The mean score on the SIE
questionnaire was 4.1 (SD  0.8; range 1.0 to 5.0). All item-total Spearman correla-
tions were greater than 0.30 (range 0.34 to 0.79) and the SIE questionnaire demon-
strated excellent overall internal reliability (Cronbach’s alpha 0.82). Based on the
eigenvalues and scree plot of the principal components analysis, a single compo-
nent was extracted, with 58.6% of total variation explained. CONCLUSIONS: The
5-item SIE questionnaire exhibited good psychometric properties, including evi-
dence of reliability and content validity. Furthermore, this sample of MS patients,
who were long-term users of GA, reported high levels of satisfaction with their
injection experience.
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OBJECTIVES: To assess in short-term changes in employment status in relapsing-
remittingmultiple sclerosis (RRMS) patients are treated with either oral, once daily
placebo, once daily Laquinimod 0.6mg or weekly intramuscular (IM) injections of
Interferon beta 1a. METHODS: Patients residing within the United States (n  xx)
with RRMS and Expanded Disability Status Scale (EDSS)  5.5 were randomly as-
signed to receive Laquinimod 0.6mg once daily, oral placebo once daily or Inter-
feron -1a 30mcg intramuscular injection weekly in the randomized, placebo con-
trolled BRAVO trial. U.S. patients completed the validated Work Productivity and
Activity Impairment Scale-General Health (WPAI-GH) at baseline and every three
months thereafter. At study completion, patient’s transitions from 1) unemploy-
ment to employment; 2) no transition in employment; and 3) transitions from
unemployment to employment were assessed using univariate statistics.
RESULTS: Sixty-two patients residing in the United States completed theWPAI-GH
with comparable study populations assigned to each of the three study arms. Sta-
tistically significant differences were observed across the three treatment arms
when consideration was given to changes in employment status (p  0.001). Sev-
enty-seven percent of patients treatedwith Avonex reported no change in employ-
ment status during the course of the study while 81% of patients in each of the
Laquinimod or placebo arm reported no change. Patients enrolled in the Avonex
group report the greatest transition from employment to unemployment (18%)
compared to Laquinimod (9%) and placebo (6%). CONCLUSIONS: Managed care
pharmacists consider multiple factors when making formulary decisions. While
safety and efficacy are the primary considerations, other factors that influence
patients and employers are frequently evaluated. While exploratory in nature,
variations in changes in employment status may occur in RRMS patients treated
with alternative diseasemodifying therapies. These findings, however, are prelim-
inary in nature and warrant future consideration through additional research.
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OBJECTIVES: Emerging data suggest that even mild or subclinical mobility loss
associated withmultiple sclerosis (MS) may adversely affect health-related quality
of life (HrQoL). We evaluated the impact and timing of mobility impairment on
HrQoL. METHODS: The North American Committee on Multiple Sclerosis (NAR-
COMS) registry was used to conduct a cross-sectional study of participants who
completed the biannual update and supplemental Spring 2010 surveys. The NAR-
COMS Performance Scale for mobility was used to grade severity of mobility im-
pairment. HrQoL assessments included the Short Form(SF)-12, physical andmental
subscales (PCS and MCS), the EuroQoL (EQ)-5D, EQ-Visual Analog Scale (VAS), and
SF-6D. RESULTS: A total of 3483 registrants completed both surveys. Compared
with those rating themselves as “normal” (n628) on the mobility performance
scale, participants describing their disability as “minimal” (n566), “mild” (n535),
“occasional support usage” (n535), “frequent cane usage” (n527), “severe”
(n543), and “total” (n105) each reported poorer HrQoL scores on the PCS and
MCS (PCS range: 53.6-30.5, MCS range: 46.8-40.3; p0.001 for all). The largest rela-
tive decrement in PCS andMCS came at the transition from “normal” to “minimal”
(PCS: 15.1%, MCS: 6.2%) and “minimal” to “mild” mobility impairment (PCS: 15.4%,
MCS: 5.9%), with the detrimental effect of poorer mobility more profound on the
PCS, and little effect on the MCS after the earlier stages of mobility impairment.
Poorer health utility was also reported in participants in impairedmobility catego-
ries compared to “normal” when examined using each of the utility measures
(EQ-5D range: 0.89-0.53, EQ-VAS range: 0.83-0.55, SF-6D range: 0.78-0.58; p0.001
for all). The largest decrements in utility came at the transition from “normal” to
“minimal” (9.6%-10.3%) and “minimal” to “mild” mobility impairment (an addi-
tional 8.6%-10.7%). CONCLUSIONS: These data suggest that mobility impairment
may negatively affect HrQoL, with the most profound decrements occurring at
earlier stages of mobility loss.
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OBJECTIVES: To evaluate associations between changes in health status over time
and health-related quality of life (HRQOL) using the Cystic Fibrosis Questionnaire-
Revised (CFQ-R), a disease-specific patient-reported outcome (PRO) measure of
HRQOL. METHODS: Using the Epidemiologic Study of Cystic Fibrosis (ESCF) data,
we identified participants who had completed age-appropriate CFQ-R assessments
on 2 occasions separated by 9 to 15months.We developedmultivariable regression
models to test whether associations existed between 1) changes in respiratory
signs/symptoms and changes in the respiratory health domains of the CFQ-R; 2)
changes in nutritional health status and changes in the nutritional health domains
of the CFQ-R; and 3) changes in treatment complexity and changes in the Treat-
ment Burden scale of the CFQ-R. RESULTS:Weanalyzed 1947 pairs of assessments:
337 child (8.9, range 6-13 years), 581 parent (mean age of child 8.8, range 6-13 years),
398 adolescent (mean age 15.3, range 14-17 years), and 631 adult (mean age 26.9,
range 18-73 years). On average, we found little change in both health status indi-
cators and CFQ-R domain scores over 1 year. Significant associations over time,
however, were found with declining weight and worsening scores on the CFQ-R
nutritional health domains, and increases in treatment complexity and worsening
CFQ-R Treatment Burden scores for parent respondents. CONCLUSIONS: Health
status and HRQOL changes were small over a 1-year period in this CF population.
Changes in respiratory symptoms and weight, however, were associated with sig-
nificant changes on relevant CFQ-R scores, indicating that this PRO is sensitive to
changes in health status over time.
NEUROLOGICAL DISORDERS – Health Care Use & Policy Studies
PND47
RESCUE MEDICATION USE IN THE ACUTE TREATMENT OF MIGRAINE DURING
MAP0004 PIVOTAL TRIAL
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OBJECTIVES: This post hoc analysis evaluated the use of rescue medication in the
acute treatment of migraine episodes reported during a randomized, placebo-con-
trolled, double-blind trial of MAP0004, an investigational, orally inhaled
dihydroergotamine. METHODS: Rescue medication use (RMU) was permitted in
this study if migraine symptomswere not relieved 2 hours after study drug admin-
istration. RMU in the MAP0004 and placebo treatment groups were adjusted for
baseline pain scores and compared according to demographic and baseline disease
characteristics (eg, age, gender, race, migraine history, baseline pain severity). The
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relationship between RMU and migraine symptom end points was also assessed.
RESULTS: This post hoc analysis included 794 patients randomized (1:1) to receive
double-blind treatment with MAP0004 or placebo. The primary results of the study
were previously published. Patients were well matched for demographic and base-
line characteristics. Patients receiving MAP0004 experienced statistically signifi-
cantmigraine symptom reduction comparedwith patients receiving placebo. RMU
in the double-blind periodwas consistently lower withMAP0004 thanwith placebo
at 2 hours (4% vs. 8%, P0.0261), 4 hours (19% vs 37%, P0.0001), 24 hours (36% vs.
54%, P0.0001), and 48 hours (42% vs. 59%, P0.0001) after study-drug administra-
tion. RMU was also significantly lower with MAP0004 than with placebo across
demographic and baseline characteristics. Among patients who reported pain re-
lief at 2 hours, MAP0004-treated patients had significantly lower RMU at 4, 24, and
48 hours than placebo-treated patients. The overall adverse event rate was com-
parable to that of placebo. CONCLUSIONS: In this study, RMU was significantly
lower with MAP0004 than with placebo overall and across demographic and base-
line characteristics.
PND48
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OBJECTIVES: To profile real world treatment patterns of patients with tuberous
sclerosis complex (TSC) which is a genetic disease that can affect multiple organ
systems in the body.METHODS:We conducted a retrospective cohort study with a
large national healthcare claims database that consists of 39 million commercially
insured Americans between 2000 and 2009. Patients with a TSC claim and contin-
uous enrollment 12 months before and 12 months after their first TSC diagnosis
were included in the study (these selection criteria lead to the exclusion of those at
age less than one). Resource utilization rates (measured as number of claims per
patient) were examined for different provider types and places of services, and
compared between the year before and after the first TSC diagnosis. Two-tail
paired sample dependent t test and Chi-square test were used for pre-post com-
parisons as well as cross-region comparison. RESULTS: The included patients
(N1249) had a mean age of 33.9 years at their first TSC diagnosis, and 57.5% were
female. Resource utilization rates with significant pre-post differences were inpa-
tient admissions (0.16 vs. 0.08, p0.01), emergency care (1.14 vs. 0.78, p0.05),
hospital outpatient care (12.68 vs. 6.66, p0.05), neurologist care (0.60 vs. 0.32,
p0.05), neurological surgeon care (0.06 vs. 0.02, p0.05), oncologist care (0.32 vs.
0.12, p0.05), and the use of anti-epilepsy medications (2.45 vs. 2.10, p0.05). The
most common places of care were physician offices (21.44), hospital outpatient
departments (12.68) and specialty care facilities (8.37); the most common provider
specialties were primary care providers (6.07), neurologists (0.60), oncologists
(0.32), surgeons (0.29); and the most common class of medications were anti-epi-
lepsymedications (2.45). Significant cross-region variations in TSCmedication uti-
lization and costs were also observed (p0.05). CONCLUSIONS: TSC patients had a
very diverse treatment profile due to its multi-organ involvement. Future research
is needed to explore the driving forces behind cross-region variations in TSC treat-
ment.
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OBJECTIVES:To investigate Parkinson’s disease (PD)medication initiation patterns
based upon diagnosing physician specialty. METHODS: Data were obtained from
the i3 InVision™ Data Mart database from January 1, 2006 through March 30, 2011.
Patients included in the analyses were diagnosed with PD (initial diagnosis identi-
fied as index date) and had continuous insurance coverage from 6 months prior
through 12 months post index date, and were at least age 35. Categorical variables
were examined using chi-square statistics while continuous variables were exam-
ined using t-tests; all are descriptive. RESULTS:A total of 5967 patients fit the study
criteria. Patients diagnosed by a neurologist (N3173), compared to those diag-
nosed by another physician specialty, were more likely to be male (58.86% vs.
53.72%; P0.0002), younger (66.53 years vs. 70.81 years; P0.0001), and in better
health, as proxied by the Charlson Comorbidity Index (1.14 vs. 1.28; P0.0034).
Patients diagnosed by a neurologist were significantly more likely to be treated
with a PD medication during the study period (48.91% vs. 30.06%; P0.0001). A
neurologist was significantly more likely to initially prescribe a monoamine
oxidase B inhibitor (MAO-B) (21.07% vs. 12.86%; P0.0001) or carbidopa/
levodopa/entacapone (9.86% vs. 6.43%; P0.0004), than a physician of another
specialty, but significantly less likely to initially prescribe carbidopa/levodopa
(27.90% vs. 42.38%; P0.0001). There was no difference in the rates of switching
from initial class of PD medication or adjunctive use of an additional class of PD
medication, although among patients prescribed multiple classes of PD medi-
cations, patients diagnosed by a neurologist were more likely to be prescribed a
dopamine agonist in combination with a MAO-B (40.08% vs. 27.34%; P0.0147).
CONCLUSIONS: These analyses found differences in treatment patterns based
upon the specialty of the diagnosing physician. Additional studies are war-
ranted to raise awareness of differences in PD treatment by diagnosing physi-
cian and to address potential health care disparities.
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OBJECTIVES: Evaluate diagnosis and treatment initiation patterns in Parkinson’s
disease (PD) based upon age. METHODS: Data were obtained from the i3 InVi-
sionTM Data Mart database from January 1, 2006 through March 30, 2011. Patients
were diagnosed with PD (initial diagnosis identified as index date), had continuous
insurance coverage from 6 months prior through 12 months post index date and
were at least 35 years old. Cohorts were divided into those under 65 and over 65
years of age. These analyses are descriptive, with continuous variables examined
using t-tests and categorical variables examined using chi-square statistics.
RESULTS: A total of 5,967 patients fit the inclusion criteria. More individuals
(58.22%) were age 65 or older, and in worse physical health, evidenced by a signif-
icantly higher pre-period Charlson score (1.52 vs. 0.77; P0.0001) and had higher
rates of pre-period cerebrovascular disease (21.53% vs. 9.07%; P0.0001), cardiovas-
cular disease (22.86% vs. 8.10%; P0.0001), dementia (10.22% vs. 1.60%; P0.0001),
diabetes (22.77% vs. 14.64%; P0.0001), hypertension (56.99% vs. 35.10%; P0.0001),
and psychoses (15.03% vs. 9.51%; P0.0001). Individuals age 65were significantly
less likely to be treatedwith PDmedication (35.69% vs. 46.21%; P0.0001), andmore
likely to be diagnosed by a neurologist (61.37% vs. 48.29%; P0.0001). Older individ-
uals were more likely to be initially prescribed carbidopa/levodopa (44.27% vs.
20.83%; P0.0001), a catechol o-methyltransferase inhibitor (5.08% vs. 2.25%;
P0.0003), or carbidopa/levodopa/entacapone (10.81% vs. 6.34%; P0.0001), but sig-
nificantly less likely to be initially prescribed a dopamine agonist (32.42% vs.
47.14%; P0.0001), amonamine oxidase B inhibitor (12.50%vs. 24.31%; P0.0001), or
an anticholinergic (3.31% vs. 6.83%; P0.0001). There was no significant difference
between rates of switching from initially prescribedmedication (18.63% vs. 21.53%;
P0.0767), although younger individuals were more likely to add an additional
class of therapy (18.40% vs. 13.15%; P0.0004). CONCLUSIONS: These analyses
highlighted potential age disparities in treatment patterns.
PND51
THE IMPACT OF PATIENT SEX ON PATTERNS OF DIAGNOSIS AND TREATMENT
AMONG PATIENTS WITH PARKINSON’S DISEASE
Grubb E1, Lage MJ2
1Teva Pharmaceuticals, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Delray
Beach, FL, USA
OBJECTIVES: To evaluate diagnosis and treatment initiation patterns in Parkin-
son’s disease (PD) based upon patient sex.METHODS:Data used for these analyses
were obtained from the i3 InVisionTM Data Mart database from January 1, 2006
through March 30, 2011. Patients were included in the analyses if they were diag-
nosedwith PD (initial diagnosis identified as index date) had continuous insurance
coverage from6months prior through 12months post index date, andwere at least
35 years old. The analyses are descriptive, with differences in continuous variables
examined using t-tests and differences in categorical variables examined using
chi-square statistics. RESULTS: A total 5967 patients who fit the inclusion and
exclusion criteria. Results revealed significant differences based on sex. More men
(56.29%) than women were diagnosed with PD, and men were in worse overall
physical health as evidenced by a significantly higher pre-period Charlson score
(1.10 vs. 1.29; P0.0001) and higher rates of pre-period diagnoses of cardiovascular
disease (21.05% vs. 11.08%; P0.0001), diabetes (20.06% vs. 17.71%; P0.0043), and
high cholesterol (38.67% vs. 34.05%; P0.0002). Female patients, however, were
more likely to be diagnosed with mental-health comorbidities, such as anxiety
(8.93% vs. 5.45%; P0.0001), depression (16.53% vs. 11.34%; P0.0001), or psychoses
(14.46% vs. 11.37%; P0.0004). Males were significantly more likely to receive PD
medication (43.55% vs. 35.68%; P0.0001) and were more likely to be diagnosed by
a neurologist (55.31% vs. 50.42%; P0.0008). Maleswere also found to bemore likely
to be initially prescribed a monamine oxidase B inhibitor (20.16% vs. 15.07%;
P0.0016). There was no significant difference between males and females with
regards to rates of switching from initially prescribed medication (20.37% vs.
19.48%; P0.5978) or adding an additional therapy to their initial regime (16.47% vs.
14.42%; P0.1792). CONCLUSIONS: These analyses highlight potential sex dispar-
ities in treatment patterns.
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DETERMINING THE EXISTENCE OF RACIAL AND ETHNIC DISPARITIES IN
ALZHEIMER’S DISEASE PHARMACOTHERAPY EXPOSURE: AN ANALYSIS ACROSS
FOUR STATE MEDICAID POPULATIONS
Gilligan A, Malone D, Warholak TL, Armstrong EP
University of Arizona, Tucson, AZ, USA
OBJECTIVES: The objective of this study was to determine if an association existed
between race/ethnicity and exposure to Alzheimer’s disease (AD) pharmacother-
apy across four state Medicaid populations. METHODS: Data from the Centers for
Medicare and Medicaid services was used in this retrospective study. Individuals
had to have an AD diagnosis (ICD-9 code 331.0) and be enrolled in a California,
Florida, New Jersey, or New York Medicaid program during 2004. Outcomes of
interest were exposure to a cholinesterase inhibitor (ChEI) or memantine. Multi-
variate logistic regression was used to test for the association between race/eth-
nicity and the exposure to a ChEI or memantine. Variables of interest included
demographic characteristics and resource utilization factors. The Oaxaca-Blinder
decomposition method to test for disparities was used to determine if exposure to
a ChEI or memantine was influenced by race. RESULTS: Approximately 158,974
individuals qualified for this study. Race, age, long-term care admittance, inpatient
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